Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Dulaglutide (Trulicity) vs Retatrutide
An educational, source-based comparison of Dulaglutide (Trulicity) and Retatrutide — how each peptide works, what it's researched for, and what to know before going deeper.
Once-weekly GLP-1 agonist with cardiovascular benefit.
GLP-1 analog fused to a modified human IgG4 Fc fragment, giving a half-life that supports weekly dosing. Improves glycemia and reduces MACE in T2D.
- Type 2 diabetes
- Cardiovascular risk reduction in T2D
- • FDA-approved.
- • Boxed warning: thyroid C-cell tumors in rodents.
A synthetic peptide that simultaneously agonizes GLP-1, GIP, and glucagon receptors. The glucagon component is hypothesized to add energy expenditure on top of the appetite suppression and insulinotropic effects of GLP-1/GIP.
- Obesity and weight loss (Phase 3)
- Type 2 diabetes
- NAFLD/MASH
- • Investigational; not FDA-approved (Phase 3 ongoing).
- • GI side effects common, similar to other incretin therapies.
- • Requires physician oversight.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Dulaglutide (Trulicity) | REWIND trial | Lancet | 2019 | Reduced major adverse cardiovascular events in T2D patients with or without prior CV disease. |
| Retatrutide | Triple-hormone-receptor agonist retatrutide for obesity | New England Journal of Medicine | 2023 | Phase 2 trial showed up to ~24% body weight reduction at 48 weeks. |
Side-effect & safety grid
- FDA-approved.
- Boxed warning: thyroid C-cell tumors in rodents.
- Investigational; not FDA-approved (Phase 3 ongoing).
- GI side effects common, similar to other incretin therapies.
- Requires physician oversight.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Dulaglutide (Trulicity) vs Retatrutide — Key differences
- Class: Dulaglutide (Trulicity) is classified as GLP-1 Agonist · Metabolic, while Retatrutide is Metabolic · Incretin.
- Primary research focus: Dulaglutide (Trulicity) — type 2 diabetes; Retatrutide — obesity and weight loss (phase 3).
- Tag: FDA-Approved · Metabolic vs Weight loss.